Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share

Emmaus Life Sciences, Inc.

2025-Q1 EPS reported -$0.04 revenue$2,406,000

Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
Loss from operations of $1.9M vs income of $3.5M in 2023.
Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.
Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.
Management expects 2025 net revenues to reach or exceed 2024 levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.